Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Individualized therapies for treating type 2 diabetes recommended

Chevy Chase, MD-Patients with type 2 diabetes are generally treated similarly despite the fact that they may have underlying differences that could affect their therapeutic response. Seeking to address this critical health issue, an international multidisciplinary group of experts just issued recommendations for individualized treatment in a consensus statement to be published in the April 2010 issue of the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

5 Apr 2010

Cellvax moves to new laboratory facility in ENVA

Cellvax is a French service company which provides complete in vitro & in vivo preclinical innovating services allowing to accelerate the drug development process for unmet needs related with severe human diseases, mainly in oncology field.

3 Apr 2010

Metabolon awarded U.S. patents for metabolomics methods

Metabolon, Inc., the leader in global metabolism through biomarker discovery and analysis, announced today the grant of US Patent 7,682,783 and US Patent 7,682,784 entitled "Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics". The USPTO awarded the patents to Metabolon on March 23, 2010. The issued claims in the new patents are for uses of metabolomics to identify diagnostic biomarkers for depression and schizophrenia by profiling classes of metabolites in a sample.

1 Apr 2010

ADDF grants Signum Biosciences $270,000 for evaluating PP2A-modulatory compounds as AD therapeutics

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is providing a grant of $270,000 to Signum Biosciences, Inc. (Princeton, NJ) to evaluate small-molecule, orally delivered Protein Phosphatase 2a (PP2A)-modulatory compounds as disease-modifying therapeutics for Alzheimer's disease.

1 Apr 2010

FDA accepts for review Abbott's novel diagnostic test for rapid detection of NGAL

A novel diagnostic test to rapidly detect neutrophil gelatinase-associated lipocalin (NGAL), an early biomarker that identifies patients at risk for acute kidney injury (AKI), has been accepted for review by the United States Food and Drug Administration. If approved, this would be the first test available for use in the United States for the detection of NGAL.

1 Apr 2010

Rosetta Genomics reports revenues of $150,000 for full-year 2009

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported that on March 26, 2010 the Company filed its Form 20-F with the U.S. Securities and Exchange Committee, which contains financial results for the three and 12 months ended December 31, 2009.

31 Mar 2010

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

ArQule, Inc. today announced that ARQ 197, when used in combination with erlotinib, demonstrated a 66% improvement in median Progression-Free Survival in patients with advanced, refractory non-small cell lung cancer.

31 Mar 2010

Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD

Clinical Data, Inc., today announced results from two Phase I studies of Stedivaze™ (apadenoson), which demonstrated that Stedivaze was safe and well tolerated in patients with asthma and chronic obstructive pulmonary disease (COPD). Stedivaze is a potent and highly selective agonist of the adenosine A2A receptor subtype in development as a pharmacologic stress agent for myocardial perfusion imaging (MPI).

30 Mar 2010

Intellikine, Tragara Pharmaceuticals awarded $1M each for developing new multiple myeloma therapies

The Multiple Myeloma Research Foundation (MMRF) today announced that two San Diego area biotech firms, Intellikine and Tragara Pharmaceuticals, Inc. will receive funding via its MMRF Biotech Investment Award program. The MMRF Biotech Investment Awards represent a multi-year research grant commitment to fund the early-stage drug development of novel compounds and approaches that show potential in treating multiple myeloma. Based on the companies' achievement of clearly defined milestones, the MMRF will commit a total of $1,000,000 to each company by the end of 2011.

30 Mar 2010

SMARTube technology helps physicians create index to get accurate picture of HIV infection

New data presented at the Center for Disease Control -sponsored 2010 HIV Diagnostics Conference suggests that an assay based on SMARTube™ technology may prove useful in developing a standardized measure for estimating what proportion of those infected with HIV have become recently infected.

29 Mar 2010

Abnormality on chromosome 17 helps detect breast cancer tumour's response to anthracyclines

British researchers have discovered a new way of detecting which breast cancer patients are going to respond best to chemotherapy that includes anthracycline antibiotics. The study has found that an abnormality on chromosome 17, called CEP17, is not only associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumour will respond to anthracyclines. The research will be presented at the European Breast Cancer Conference (EBCC7) Thursday 25th March.

26 Mar 2010

Treatment with beta-blockers can help reduce spread of cancer in patients with breast tumours

Treatment with beta-blockers can help reduce the spread of cancer in patients with breast tumours, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today (Friday).

26 Mar 2010

FIMM to launch cell microarray screening research program utilizing Aushon 2470 Arrayer technology

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis announced today that the Institute for Molecular Medicine Finland will launch a cell microarray screening research program utilizing the Aushon 2470 Arrayer technology.

26 Mar 2010

Eli Lilly supports SNM's initiative to advance innovative therapies

SNM is pleased to announce that biopharmaceutical company, Eli Lilly and Company, has joined SNM's Clinical Trials Network-making it the third major company to formally support this initiative to facilitate the development of promising therapeutic medicines.

26 Mar 2010

SMA Foundation completes biomarker study for Spinal Muscular Atrophy

The Spinal Muscular Atrophy (SMA) Foundation, a nonprofit organization dedicated to accelerating the development of a treatment for SMA, is pleased to announce the completion of a pilot study to identify Biomarkers for Spinal Muscular Atrophy (BforSMA) and the discovery of over 400 candidate biomarkers.

26 Mar 2010

Fluidigm, SABiosciences partner to create pathway-focused gene expression panels for BioMark system

Fluidigm Corporation and SABiosciences (a QIAGEN Company) today announced that they have teamed up to create over 100 pathway-focused gene expression panels validated for real-time PCR analysis on the Fluidigm BioMark™ System for Genetic Analysis. These kits are named the RT² Profiler™ PCR Arrays for the Fluidigm BioMark system.

26 Mar 2010

VisEn Medical announces launch of new GastroSense 750 fluorescence agent for imaging gastric motility

VisEn Medical Inc., a leader in fluorescence imaging from research through medicine, announced today the commercial launch of its new GastroSense™ 750 fluorescence agent for imaging gastric motility and related drug effects in vivo.

26 Mar 2010

Tips offered in April 2010 issue of American Journal Of Pathology

A group led by Dr. Massimo Loda at the Dana Farber Cancer Institute, Boston, MA has generated a preclinical model of human prostate cancer that mimics the genetic and growth behavior of primary tumors. Their report can be found in the April 2010 issue of the American Journal of Pathology.

25 Mar 2010

Life Technologies' real-time PCR instrument available for IVD use in Europe

Life Technologies Corporation (NASDAQ: LIFE) today announced that its Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument is available as a platform suitable for in vitro diagnostics (IVD) use in Europe. Clinical laboratories from 22 countries and European institutions that develop in vitro molecular diagnostic assays in oncology, genetic disease and infectious disease will now be able to leverage the instrument’s regulatory clearance to develop tests for clinical applications.

24 Mar 2010

Clinical Data completes NDA submission for vilazodone

Clinical Data, Inc., today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vilazodone for the treatment of major depressive disorder (MDD). Vilazodone is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. The Company expects that the NDA submission, if accepted, will be subject to a standard review.

23 Mar 2010

Biomarker News and Research

Further Reading

Individualized therapies for treating type 2 diabetes recommended

Cellvax moves to new laboratory facility in ENVA

Metabolon awarded U.S. patents for metabolomics methods

ADDF grants Signum Biosciences $270,000 for evaluating PP2A-modulatory compounds as AD therapeutics

FDA accepts for review Abbott's novel diagnostic test for rapid detection of NGAL

Rosetta Genomics reports revenues of $150,000 for full-year 2009

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD

Intellikine, Tragara Pharmaceuticals awarded $1M each for developing new multiple myeloma therapies

SMARTube technology helps physicians create index to get accurate picture of HIV infection

Abnormality on chromosome 17 helps detect breast cancer tumour's response to anthracyclines

Treatment with beta-blockers can help reduce spread of cancer in patients with breast tumours

FIMM to launch cell microarray screening research program utilizing Aushon 2470 Arrayer technology

Eli Lilly supports SNM's initiative to advance innovative therapies

SMA Foundation completes biomarker study for Spinal Muscular Atrophy

Fluidigm, SABiosciences partner to create pathway-focused gene expression panels for BioMark system

VisEn Medical announces launch of new GastroSense 750 fluorescence agent for imaging gastric motility

Tips offered in April 2010 issue of American Journal Of Pathology

Life Technologies' real-time PCR instrument available for IVD use in Europe

Clinical Data completes NDA submission for vilazodone

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News